TX-VENTURE-OUTSOURCE
9.11.2021 15:12:09 CET | Business Wire | Press release
Venture Outsource, LLC, a leader in contract electronics sourcing knowledge strategy, today announces, its next online training seminar for electronics OEM equipment manufacturers tasked with sourcing contract electronics manufacturing services (EMS). The next online seminar will be December 8, 2021.
Register: https://www.ventureoutsource.com/ems-manufacturing-costing-tools
The seminar is for electronics professionals in commodity procurement, strategic sourcing, purchasing cost estimation, pricing analysis, supplier development, supply chain management, and related, to help decision makers better plan and formulate budgets and spend when contracting and managing EMS manufacturing services, while staying ahead of EMS supplier costs and contract pricing negotiations.
"Our cost modelers are an essential point of reference helping electronic OEM equipment manufacturers make more informed decisions. Seminar attendees get benefits in many directions, able to connect the dots between their decisions and their consequences," says Venture Outsource president, Mark Zetter.
Why attend?
Each registered attendee receives an 'EMS Manufacturing Programs Cost Modeler Compendium’ and certificate upon completion of the virtual lab. Some key takeaways:
- Determine EMS provider 'internal cost' for your EMS program (vs EMS quote pricing)
- Identify areas in your EMS program or quote, where EMS providers are charging excessive fees
- Determine optimal EMS program Total Landed Cost per geography
- Using 'EMS Manufacturing Programs Cost Modeler Compendium' outputs to forecast EMS program costs and formulate strategy for EMS contract service agreement pricing negotiations, structuring contract clauses, and cost reduction strategies with EMS manufacturing partners
Register: https://www.ventureoutsource.com/ems-manufacturing-costing-tools
Industry professionals using the ‘EMS Manufacturing Programs Cost Modeler Compendium’ save, on average, between 5% and 15%+ of EMS manufacturing program annual spend.
For example:
An electronics OEM paying its EMS manufacturing partner $45 million for one year of services. With just a 5% reduction in OEM accounts payable to this EMS provider, the OEM cost reduction opportunity is $2.5 million, where:
Annual EMS Program Spend $45,0000,000 x .05 = $2,500,000 OEM Savings
About Venture Outsource, LLC
Venture Outsource, LLC is the leading top-down, thematic, contract electronics advisory with an esoteric approach to contract manufacturing supply chain problem solving. Our EMS sourcing cost models are used across a variety of electronics industry markets and segments, manufacturing program sizes and volumes, and geographies. Visit: ventureoutsource.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211109005004/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom